Jaguar Health Files 8-K on Shareholder Votes & Financials

TL;DR

Jaguar Health (JAGX) filed an 8-K detailing shareholder votes and financials.

AI Summary

Jaguar Health, Inc. filed an 8-K on December 8, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial statements. The filing also noted the company's former name, Jaguar Animal Health, Inc., which was changed on August 30, 2013.

Why It Matters

This 8-K filing provides updates on important corporate actions and financial reporting, which are crucial for investors to understand the company's governance and financial health.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting on corporate events and financial statements, not indicating any immediate operational or financial distress.

Key Players & Entities

• Jaguar Health, Inc. (company) — Registrant
• Jaguar Animal Health, Inc. (company) — Former company name
• December 08, 2025 (date) — Date of report
• August 30, 2013 (date) — Date of name change
• 001-36714 (other) — SEC file number

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Stock Mar

Filing Documents

• jagx-20251208.htm (8-K) — 73KB
• jagx-ex99_1.htm (EX-99.1) — 20KB
• img107817981_0.jpg (GRAPHIC) — 85KB
• 0001193125-25-311294.txt ( ) — 320KB
• jagx-20251208.xsd (EX-101.SCH) — 24KB
• jagx-20251208_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On December 8, 2025, Jaguar Health, Inc. (the "Company") held a special meeting of stockholders of the Company (the "Special Meeting"). Three proposals were submitted to and approved by the Company's stockholders. The proposals are described in details in the Company's definitive proxy statement for the Special Meeting (the "Proxy Statement"), filed with the Securities and Exchange Commission on November 10, 2025. At the Special Meeting, (i) a total of 747,205 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), out of a total of 3,735,835 shares of Common Stock issued and outstanding and entitled to vote at the Special Meeting, (ii) a total of 121.3822 shares of the Company's Series L Perpetual Preferred Stock, par value $0.0001 per share (the "Series L Preferred Stock"), representing all of the issued and outstanding shares of Series L Preferred Stock entitled to vote at the Special Meeting, (iii) a total of 235 shares of the Company's Series M Perpetual Preferred Stock, par value $0.0001 per share (the "Series M Preferred Stock"), out of a total of 260 shares of Series M Preferred Stock issued and outstanding and entitled to vote at the Special Meeting, and (iv) a total of 810.8 shares of the Company's Series N Perpetual Preferred Stock, par value $0.0001 per share (the "Series N Preferred Stock"), out of a total of 950.8 shares of Series N Preferred Stock issued and outstanding and entitled to vote at the Special Meeting, each as of October 31, 2025, the record date for the Special Meeting, were represented in person or by proxy at the Special Meeting. As described in the Proxy Statement, (i) each share of Series L Preferred Stock entitles the holder of record thereof to 3,787 votes (on an as converted to Common Stock basis); provided, that, any holder of Series L Preferred Stock is not entitled to vote, on an as-converted basis and in the aggregate with respect t

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 8, 2025, the Company issued a press release announcing the results of the Special Meeting, a copy of which is furnished as Exhibit 99.1. The information in Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated December 8, 2025 104 Cover Page Interactive Data File (embedded with the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAGUAR HEALTH, INC Date: December 8, 2025 By: /s/ Lisa A. Conte Lisa A. Conte Chief Executive Officer & President